phenylacetic acid has been researched along with Cell Transformation, Neoplastic in 7 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some thyroid cancers are or become dedifferentiated, and they become refractory to efficacy-proven conventional therapies such as radioiodine ablation therapy and thyrotropin (TSH)-suppressive therapy." | 2.42 | Redifferentiation therapy for thyroid cancer. ( Clark, OH; Park, JW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JW | 1 |
| Clark, OH | 1 |
| Shack, S | 3 |
| Chen, LC | 1 |
| Miller, AC | 2 |
| Danesi, R | 1 |
| Samid, D | 3 |
| Prasanna, P | 1 |
| Wilson, VL | 1 |
| Myers, CE | 1 |
| Xu, J | 1 |
| Stewart, M | 1 |
| McClain, D | 1 |
| Watanabe, M | 1 |
| Sugano, S | 1 |
| Imai, J | 1 |
| Yoshida, K | 1 |
| Onodera, R | 1 |
| Amin, MR | 1 |
| Uchida, K | 1 |
| Yamaguchi, R | 1 |
| Tateyama, S | 1 |
| Sherman, LT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy[NCT00001565] | Phase 1 | 35 participants | Interventional | 1996-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for phenylacetic acid and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Redifferentiation therapy for thyroid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Transformation, Neoplastic; | 2004 |
Differentiating agents and nontoxic therapies.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Fatty Acids; Humans; Male; Phenylacetates; P | 1999 |
5 other studies available for phenylacetic acid and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Transformation, Neop | 1995 |
Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis.
Topics: 3T3 Cells; Animals; Anticarcinogenic Agents; Azacitidine; Carcinogens; Cell Division; Cell Transform | 1995 |
Suppression of depleted uranium-induced neoplastic transformation of human cells by the phenyl fatty acid, phenyl acetate: chemoprevention by targeting the p21RAS protein pathway.
Topics: Animals; Anticarcinogenic Agents; Bone Neoplasms; Cell Transformation, Neoplastic; Female; Humans; M | 2001 |
Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumour cell line MCM-B2 by sodium phenylacetate.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Division; Cell Transformation, | 2001 |
Phenylacetate: a novel nontoxic inducer of tumor cell differentiation.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Division; Ce | 1992 |